Drugs / RC118
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04914117 | Nov 2021 → Nov 2022 | metastatic neoplasm | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06038396 | Aug 2023 → Feb 2026 overdue | neoplasm | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04914117 ↗ |
| Route | Intravenous | “RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.” NCT04914117 ↗ |